RU2663354C2 - Композиции и способы для модификации заданной последовательности нуклеиновой кислоты-мишени - Google Patents
Композиции и способы для модификации заданной последовательности нуклеиновой кислоты-мишени Download PDFInfo
- Publication number
- RU2663354C2 RU2663354C2 RU2014129015A RU2014129015A RU2663354C2 RU 2663354 C2 RU2663354 C2 RU 2663354C2 RU 2014129015 A RU2014129015 A RU 2014129015A RU 2014129015 A RU2014129015 A RU 2014129015A RU 2663354 C2 RU2663354 C2 RU 2663354C2
- Authority
- RU
- Russia
- Prior art keywords
- nucleic acid
- scna
- target
- sequence
- dna
- Prior art date
Links
- 150000007523 nucleic acids Chemical group 0.000 title claims abstract description 505
- 238000000034 method Methods 0.000 title claims abstract description 112
- 238000012986 modification Methods 0.000 title claims abstract description 110
- 230000004048 modification Effects 0.000 title claims abstract description 106
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 89
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 429
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 429
- 239000002773 nucleotide Substances 0.000 claims abstract description 212
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 212
- 230000027455 binding Effects 0.000 claims abstract description 203
- 238000009739 binding Methods 0.000 claims abstract description 203
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 66
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 59
- 229920001184 polypeptide Polymers 0.000 claims abstract description 57
- 239000013598 vector Substances 0.000 claims abstract description 56
- 230000000295 complement effect Effects 0.000 claims abstract description 45
- 102000011931 Nucleoproteins Human genes 0.000 claims abstract description 30
- 108010061100 Nucleoproteins Proteins 0.000 claims abstract description 30
- 230000000051 modifying effect Effects 0.000 claims abstract description 24
- 230000009870 specific binding Effects 0.000 claims abstract description 8
- 108020004414 DNA Proteins 0.000 claims description 243
- 108090000623 proteins and genes Proteins 0.000 claims description 215
- 210000004027 cell Anatomy 0.000 claims description 186
- 235000004252 protein component Nutrition 0.000 claims description 155
- 102000004169 proteins and genes Human genes 0.000 claims description 119
- 235000018102 proteins Nutrition 0.000 claims description 110
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 91
- 102000053602 DNA Human genes 0.000 claims description 76
- 230000035772 mutation Effects 0.000 claims description 69
- 101710163270 Nuclease Proteins 0.000 claims description 52
- 230000003993 interaction Effects 0.000 claims description 41
- 238000012217 deletion Methods 0.000 claims description 39
- 230000037430 deletion Effects 0.000 claims description 39
- 238000003780 insertion Methods 0.000 claims description 38
- 230000037431 insertion Effects 0.000 claims description 38
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 31
- 210000003470 mitochondria Anatomy 0.000 claims description 29
- 230000011987 methylation Effects 0.000 claims description 22
- 238000007069 methylation reaction Methods 0.000 claims description 22
- 230000006798 recombination Effects 0.000 claims description 20
- 238000005215 recombination Methods 0.000 claims description 20
- 230000002779 inactivation Effects 0.000 claims description 15
- 230000004913 activation Effects 0.000 claims description 14
- 238000001994 activation Methods 0.000 claims description 14
- -1 deacetylase Proteins 0.000 claims description 14
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 13
- 238000007385 chemical modification Methods 0.000 claims description 13
- 108060004795 Methyltransferase Proteins 0.000 claims description 11
- 108091023040 Transcription factor Proteins 0.000 claims description 10
- 230000003612 virological effect Effects 0.000 claims description 10
- 238000005304 joining Methods 0.000 claims description 9
- 230000021736 acetylation Effects 0.000 claims description 8
- 238000006640 acetylation reaction Methods 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 238000002372 labelling Methods 0.000 claims description 8
- 108010077544 Chromatin Proteins 0.000 claims description 7
- 230000004570 RNA-binding Effects 0.000 claims description 7
- 210000003483 chromatin Anatomy 0.000 claims description 7
- 210000002706 plastid Anatomy 0.000 claims description 7
- 102000055027 Protein Methyltransferases Human genes 0.000 claims description 6
- 108700040121 Protein Methyltransferases Proteins 0.000 claims description 6
- 101710183280 Topoisomerase Proteins 0.000 claims description 6
- 108010013043 Acetylesterase Proteins 0.000 claims description 4
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 claims description 4
- 102100034343 Integrase Human genes 0.000 claims description 4
- 108010061833 Integrases Proteins 0.000 claims description 4
- 102000003960 Ligases Human genes 0.000 claims description 4
- 108090000364 Ligases Proteins 0.000 claims description 4
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 claims description 4
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims description 4
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims description 4
- 102000001253 Protein Kinase Human genes 0.000 claims description 4
- 102000018120 Recombinases Human genes 0.000 claims description 4
- 108010091086 Recombinases Proteins 0.000 claims description 4
- 210000003763 chloroplast Anatomy 0.000 claims description 4
- 108060006633 protein kinase Proteins 0.000 claims description 4
- 230000000368 destabilizing effect Effects 0.000 claims description 3
- 230000005782 double-strand break Effects 0.000 claims description 3
- 230000005783 single-strand break Effects 0.000 claims description 3
- 230000010399 physical interaction Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 40
- 239000000126 substance Substances 0.000 abstract description 14
- 239000013612 plasmid Substances 0.000 description 96
- 238000003776 cleavage reaction Methods 0.000 description 75
- 230000007017 scission Effects 0.000 description 75
- 210000001938 protoplast Anatomy 0.000 description 74
- 239000000306 component Substances 0.000 description 62
- 241000196324 Embryophyta Species 0.000 description 59
- 238000001727 in vivo Methods 0.000 description 51
- 239000005090 green fluorescent protein Substances 0.000 description 47
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 45
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 45
- 230000006801 homologous recombination Effects 0.000 description 44
- 238000002744 homologous recombination Methods 0.000 description 44
- 108091034117 Oligonucleotide Proteins 0.000 description 42
- 239000000243 solution Substances 0.000 description 42
- 230000014509 gene expression Effects 0.000 description 41
- 241000589158 Agrobacterium Species 0.000 description 37
- 125000005647 linker group Chemical group 0.000 description 37
- 238000001890 transfection Methods 0.000 description 36
- 229940088598 enzyme Drugs 0.000 description 35
- 238000004458 analytical method Methods 0.000 description 33
- 125000003275 alpha amino acid group Chemical group 0.000 description 32
- 102000004190 Enzymes Human genes 0.000 description 31
- 108090000790 Enzymes Proteins 0.000 description 31
- 230000000692 anti-sense effect Effects 0.000 description 30
- 230000009471 action Effects 0.000 description 29
- 108091026890 Coding region Proteins 0.000 description 27
- 230000006870 function Effects 0.000 description 25
- 238000006471 dimerization reaction Methods 0.000 description 24
- 241000219194 Arabidopsis Species 0.000 description 22
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 description 22
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 22
- 241000700605 Viruses Species 0.000 description 21
- 101000993973 Homo sapiens Inositol-pentakisphosphate 2-kinase Proteins 0.000 description 20
- 102100031525 Inositol-pentakisphosphate 2-kinase Human genes 0.000 description 20
- 238000001514 detection method Methods 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 19
- 239000002609 medium Substances 0.000 description 19
- 125000006850 spacer group Chemical group 0.000 description 19
- 238000013518 transcription Methods 0.000 description 19
- 230000035897 transcription Effects 0.000 description 19
- 101710185494 Zinc finger protein Proteins 0.000 description 18
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 18
- 239000012636 effector Substances 0.000 description 18
- 230000000670 limiting effect Effects 0.000 description 18
- 210000003463 organelle Anatomy 0.000 description 18
- 238000006467 substitution reaction Methods 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 101150093272 ATP9 gene Proteins 0.000 description 17
- 108020004705 Codon Proteins 0.000 description 17
- 101710141454 Nucleoprotein Proteins 0.000 description 17
- 229920001223 polyethylene glycol Polymers 0.000 description 17
- 230000002459 sustained effect Effects 0.000 description 17
- 230000010354 integration Effects 0.000 description 16
- 210000000056 organ Anatomy 0.000 description 16
- 230000001105 regulatory effect Effects 0.000 description 16
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 15
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 15
- 206010020649 Hyperkeratosis Diseases 0.000 description 15
- 240000008042 Zea mays Species 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 15
- 230000008685 targeting Effects 0.000 description 15
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 14
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 230000003362 replicative effect Effects 0.000 description 14
- 238000012546 transfer Methods 0.000 description 14
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 13
- 101100324954 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) oli gene Proteins 0.000 description 13
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 13
- 229960005091 chloramphenicol Drugs 0.000 description 13
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- 108010060309 Glucuronidase Proteins 0.000 description 12
- 102000053187 Glucuronidase Human genes 0.000 description 12
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 12
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 12
- 240000007377 Petunia x hybrida Species 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 108010052621 fas Receptor Proteins 0.000 description 12
- 102000018823 fas Receptor Human genes 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 230000007762 localization of cell Effects 0.000 description 12
- 230000008439 repair process Effects 0.000 description 12
- 108091008146 restriction endonucleases Proteins 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 244000061176 Nicotiana tabacum Species 0.000 description 11
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 11
- 101150096101 OLI1 gene Proteins 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 230000002068 genetic effect Effects 0.000 description 11
- 230000002438 mitochondrial effect Effects 0.000 description 11
- 239000000178 monomer Substances 0.000 description 11
- 230000003321 amplification Effects 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 238000002716 delivery method Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 239000004009 herbicide Substances 0.000 description 10
- 239000003607 modifier Substances 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 9
- 238000011953 bioanalysis Methods 0.000 description 9
- 238000004166 bioassay Methods 0.000 description 9
- VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000004520 electroporation Methods 0.000 description 9
- 230000037433 frameshift Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000001338 self-assembly Methods 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 238000011191 terminal modification Methods 0.000 description 9
- 230000010474 transient expression Effects 0.000 description 9
- 238000013519 translation Methods 0.000 description 9
- 241001515965 unidentified phage Species 0.000 description 9
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 8
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 8
- 206010021929 Infertility male Diseases 0.000 description 8
- 208000007466 Male Infertility Diseases 0.000 description 8
- 108700026244 Open Reading Frames Proteins 0.000 description 8
- 229960000723 ampicillin Drugs 0.000 description 8
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 8
- 238000004364 calculation method Methods 0.000 description 8
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 8
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 8
- 239000000975 dye Substances 0.000 description 8
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 101710159080 Aconitate hydratase A Proteins 0.000 description 7
- 101710159078 Aconitate hydratase B Proteins 0.000 description 7
- 230000004568 DNA-binding Effects 0.000 description 7
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 102000016397 Methyltransferase Human genes 0.000 description 7
- 108091093037 Peptide nucleic acid Proteins 0.000 description 7
- 101710105008 RNA-binding protein Proteins 0.000 description 7
- 108091081021 Sense strand Proteins 0.000 description 7
- 239000004098 Tetracycline Substances 0.000 description 7
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000003197 catalytic effect Effects 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 210000000805 cytoplasm Anatomy 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 239000000539 dimer Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000002363 herbicidal effect Effects 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 235000009973 maize Nutrition 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000030648 nucleus localization Effects 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 239000013600 plasmid vector Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 229960002180 tetracycline Drugs 0.000 description 7
- 229930101283 tetracycline Natural products 0.000 description 7
- 235000019364 tetracycline Nutrition 0.000 description 7
- 150000003522 tetracyclines Chemical class 0.000 description 7
- 230000009261 transgenic effect Effects 0.000 description 7
- 108700028369 Alleles Proteins 0.000 description 6
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 6
- 102000040945 Transcription factor Human genes 0.000 description 6
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 6
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 235000020958 biotin Nutrition 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 235000005822 corn Nutrition 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 230000008263 repair mechanism Effects 0.000 description 6
- ZBMRKNMTMPPMMK-UHFFFAOYSA-N 2-amino-4-[hydroxy(methyl)phosphoryl]butanoic acid;azane Chemical compound [NH4+].CP(O)(=O)CCC(N)C([O-])=O ZBMRKNMTMPPMMK-UHFFFAOYSA-N 0.000 description 5
- 108010000700 Acetolactate synthase Proteins 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 238000007400 DNA extraction Methods 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108020005196 Mitochondrial DNA Proteins 0.000 description 5
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 5
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- GINJFDRNADDBIN-FXQIFTODSA-N bilanafos Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCP(C)(O)=O GINJFDRNADDBIN-FXQIFTODSA-N 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000012937 correction Methods 0.000 description 5
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000011010 flushing procedure Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 244000000056 intracellular parasite Species 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 108020001580 protein domains Proteins 0.000 description 5
- 238000004062 sedimentation Methods 0.000 description 5
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 4
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 4
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 4
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- LUCHPKXVUGJYGU-XLPZGREQSA-N 5-methyl-2'-deoxycytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LUCHPKXVUGJYGU-XLPZGREQSA-N 0.000 description 4
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 4
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 4
- 108091029845 Aminoallyl nucleotide Proteins 0.000 description 4
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 4
- 102100024811 DNA (cytosine-5)-methyltransferase 3-like Human genes 0.000 description 4
- 230000007067 DNA methylation Effects 0.000 description 4
- 230000008265 DNA repair mechanism Effects 0.000 description 4
- 241000702024 Enterobacteria phage phi21 Species 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 4
- 108060002716 Exonuclease Proteins 0.000 description 4
- 108010039471 Fas Ligand Protein Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 108010001515 Galectin 4 Proteins 0.000 description 4
- 102100039556 Galectin-4 Human genes 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 101000909250 Homo sapiens DNA (cytosine-5)-methyltransferase 3-like Proteins 0.000 description 4
- 208000026350 Inborn Genetic disease Diseases 0.000 description 4
- 101100288095 Klebsiella pneumoniae neo gene Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102000015636 Oligopeptides Human genes 0.000 description 4
- 108010038807 Oligopeptides Proteins 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 108091027981 Response element Proteins 0.000 description 4
- 108091027544 Subgenomic mRNA Proteins 0.000 description 4
- 108700026226 TATA Box Proteins 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000006154 adenylylation Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 150000001540 azides Chemical class 0.000 description 4
- 229950004398 broxuridine Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000000412 dendrimer Substances 0.000 description 4
- 229920000736 dendritic polymer Polymers 0.000 description 4
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 4
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000005546 dideoxynucleotide Substances 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 102000013165 exonuclease Human genes 0.000 description 4
- 238000012239 gene modification Methods 0.000 description 4
- 208000016361 genetic disease Diseases 0.000 description 4
- 230000001738 genotoxic effect Effects 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 230000013011 mating Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 125000002652 ribonucleotide group Chemical group 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 108091006112 ATPases Proteins 0.000 description 3
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- 108010037058 Bacterial Secretion Systems Proteins 0.000 description 3
- 101150017501 CCR5 gene Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 3
- 101710096438 DNA-binding protein Proteins 0.000 description 3
- 241000702315 Escherichia virus phiX174 Species 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 101150064015 FAS gene Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101150082027 IPK1 gene Proteins 0.000 description 3
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 101150108119 PDS gene Proteins 0.000 description 3
- 241000709664 Picornaviridae Species 0.000 description 3
- 101710149951 Protein Tat Proteins 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 241000723573 Tobacco rattle virus Species 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 3
- OJOBTAOGJIWAGB-UHFFFAOYSA-N acetosyringone Chemical compound COC1=CC(C(C)=O)=CC(OC)=C1O OJOBTAOGJIWAGB-UHFFFAOYSA-N 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 150000001345 alkine derivatives Chemical class 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000008045 co-localization Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 150000004662 dithiols Chemical class 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000008519 endogenous mechanism Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 238000010363 gene targeting Methods 0.000 description 3
- 230000005017 genetic modification Effects 0.000 description 3
- 231100000025 genetic toxicology Toxicity 0.000 description 3
- 235000013617 genetically modified food Nutrition 0.000 description 3
- 238000010362 genome editing Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 235000002949 phytic acid Nutrition 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- YVLPJIGOMTXXLP-UHFFFAOYSA-N 15-cis-phytoene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C YVLPJIGOMTXXLP-UHFFFAOYSA-N 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 101150001232 ALS gene Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 2
- 241000244203 Caenorhabditis elegans Species 0.000 description 2
- 102000009410 Chemokine receptor Human genes 0.000 description 2
- 108050000299 Chemokine receptor Proteins 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 108091029430 CpG site Proteins 0.000 description 2
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 2
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 2
- 230000009946 DNA mutation Effects 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 108091035710 E-box Proteins 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 208000015872 Gaucher disease Diseases 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Natural products O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 102000010883 K Homology domains Human genes 0.000 description 2
- 108050001040 K Homology domains Proteins 0.000 description 2
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 description 2
- 102100021174 Lipoyl synthase, mitochondrial Human genes 0.000 description 2
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 240000007652 Petunia axillaris Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 101710150344 Protein Rev Proteins 0.000 description 2
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 2
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000022292 Tay-Sachs disease Diseases 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- 238000005411 Van der Waals force Methods 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 102100023406 Zinc finger RNA-binding protein Human genes 0.000 description 2
- 101710150392 Zinc finger RNA-binding protein Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 201000006288 alpha thalassemia Diseases 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000009830 antibody antigen interaction Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 208000005980 beta thalassemia Diseases 0.000 description 2
- 238000010170 biological method Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229960003669 carbenicillin Drugs 0.000 description 2
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000010109 chemoembolization Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 231100000221 frame shift mutation induction Toxicity 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 2
- 108060004127 isopentenyl phosphate kinase Proteins 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 108010037535 lipoic acid synthase Proteins 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000010297 mechanical methods and process Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000025608 mitochondrion localization Effects 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 229910010271 silicon carbide Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 238000005829 trimerization reaction Methods 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BIWLELKAFXRPDE-UHFFFAOYSA-N zeta-Carotene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)CCC=C(C)CCC=C(C)C BIWLELKAFXRPDE-UHFFFAOYSA-N 0.000 description 2
- YVLPJIGOMTXXLP-UUKUAVTLSA-N 15,15'-cis-Phytoene Natural products C(=C\C=C/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C YVLPJIGOMTXXLP-UUKUAVTLSA-N 0.000 description 1
- YVLPJIGOMTXXLP-BAHRDPFUSA-N 15Z-phytoene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/CCC=C(/C)CCC=C(/C)CCC=C(C)C)C)C)C)C YVLPJIGOMTXXLP-BAHRDPFUSA-N 0.000 description 1
- XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- KRIDPWRYKXPBLO-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;3h-dithiole Chemical compound C1SSC=C1.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 KRIDPWRYKXPBLO-UFLZEWODSA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- ASUCSHXLTWZYBA-UMMCILCDSA-N 8-Bromoguanosine Chemical compound C1=2NC(N)=NC(=O)C=2N=C(Br)N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ASUCSHXLTWZYBA-UMMCILCDSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 102000010195 ADD domains Human genes 0.000 description 1
- 108050001756 ADD domains Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 1
- 201000010028 Acrocephalosyndactylia Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100033647 Activity-regulated cytoskeleton-associated protein Human genes 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
- 206010056292 Androgen-Insensitivity Syndrome Diseases 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000025490 Apert syndrome Diseases 0.000 description 1
- 108700004205 Arabidopsis HSP18.2 Proteins 0.000 description 1
- 101100189681 Arabidopsis thaliana PDS gene Proteins 0.000 description 1
- 102000008682 Argonaute Proteins Human genes 0.000 description 1
- 108010088141 Argonaute Proteins Proteins 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101150069409 CDS gene Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008723 Chondrodystrophy Diseases 0.000 description 1
- 201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 description 1
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 1
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 1
- 208000006992 Color Vision Defects Diseases 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 101710095827 Cyclopropane mycolic acid synthase 1 Proteins 0.000 description 1
- 101710095826 Cyclopropane mycolic acid synthase 2 Proteins 0.000 description 1
- 101710095828 Cyclopropane mycolic acid synthase 3 Proteins 0.000 description 1
- 101710110342 Cyclopropane mycolic acid synthase MmaA2 Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102400000011 Cytochrome b-c1 complex subunit 9 Human genes 0.000 description 1
- 101800000778 Cytochrome b-c1 complex subunit 9 Proteins 0.000 description 1
- 102100024810 DNA (cytosine-5)-methyltransferase 3B Human genes 0.000 description 1
- 101710123222 DNA (cytosine-5)-methyltransferase 3B Proteins 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 230000007035 DNA breakage Effects 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 102000010170 Death domains Human genes 0.000 description 1
- 108050001718 Death domains Proteins 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 239000005504 Dicamba Substances 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000027472 Galactosemias Diseases 0.000 description 1
- 108700023863 Gene Components Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 229930191978 Gibberellin Natural products 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- CTETYYAZBPJBHE-UHFFFAOYSA-N Haloprogin Chemical compound ClC1=CC(Cl)=C(OCC#CI)C=C1Cl CTETYYAZBPJBHE-UHFFFAOYSA-N 0.000 description 1
- 108010085686 Hemoglobin C Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 108010024124 Histone Deacetylase 1 Proteins 0.000 description 1
- 102000015616 Histone Deacetylase 1 Human genes 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 101710100812 Histone deacetylase HDAC1 Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101000739890 Homo sapiens D-3-phosphoglycerate dehydrogenase Proteins 0.000 description 1
- 101001116668 Homo sapiens Prefoldin subunit 3 Proteins 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 description 1
- 101710177638 Hydroxymycolate synthase MmaA4 Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010049933 Hypophosphatasia Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- YTZIWAULTIDEEY-UHFFFAOYSA-N Isomeres zeta-Carotin Natural products CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=CC=C(C)C=CC=C(C)C=CC=C(C)CCC=C(C)C YTZIWAULTIDEEY-UHFFFAOYSA-N 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 208000017924 Klinefelter Syndrome Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010050638 Langer-Giedion syndrome Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000000916 Mandibulofacial dysostosis Diseases 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 101710174850 Methoxy mycolic acid synthase MmaA3 Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241000906086 Miris Species 0.000 description 1
- 206010052641 Mitochondrial DNA mutation Diseases 0.000 description 1
- 102000013379 Mitochondrial Proton-Translocating ATPases Human genes 0.000 description 1
- 108010026155 Mitochondrial Proton-Translocating ATPases Proteins 0.000 description 1
- 201000002983 Mobius syndrome Diseases 0.000 description 1
- 208000034167 Moebius syndrome Diseases 0.000 description 1
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100365516 Mus musculus Psat1 gene Proteins 0.000 description 1
- 101710204417 Mycolic acid methyltransferase MmaA1 Proteins 0.000 description 1
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 101150036433 NAD3 gene Proteins 0.000 description 1
- 102000006746 NADH Dehydrogenase Human genes 0.000 description 1
- 108010086428 NADH Dehydrogenase Proteins 0.000 description 1
- VQAYFKKCNSOZKM-UHFFFAOYSA-N NSC 29409 Natural products C1=NC=2C(NC)=NC=NC=2N1C1OC(CO)C(O)C1O VQAYFKKCNSOZKM-UHFFFAOYSA-N 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 241000207746 Nicotiana benthamiana Species 0.000 description 1
- 101100179608 Nicotiana tabacum ALS SURB gene Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000004286 Osteochondrodysplasias Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000009353 PWWP domains Human genes 0.000 description 1
- 108050000223 PWWP domains Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- 102100024884 Prefoldin subunit 3 Human genes 0.000 description 1
- 208000007932 Progeria Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 208000007531 Proteus syndrome Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 101100024116 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MPT5 gene Proteins 0.000 description 1
- 101000785134 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Probable phospholipid-transporting ATPase DNF3 Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 201000001388 Smith-Magenis syndrome Diseases 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 208000027077 Stickler syndrome Diseases 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 241001475173 Tarsocera Species 0.000 description 1
- 201000003199 Treacher Collins syndrome Diseases 0.000 description 1
- 208000035378 Trichorhinophalangeal syndrome type 2 Diseases 0.000 description 1
- 208000037280 Trisomy Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000081472 Triticum timopheevi Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 208000026724 Waardenburg syndrome Diseases 0.000 description 1
- 206010049644 Williams syndrome Diseases 0.000 description 1
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- PPQRONHOSHZGFQ-LMVFSUKVSA-N aldehydo-D-ribose 5-phosphate Chemical group OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PPQRONHOSHZGFQ-LMVFSUKVSA-N 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000003126 arrythmogenic effect Effects 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 101150103518 bar gene Proteins 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000014884 cartilage development disease Diseases 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 201000007254 color blindness Diseases 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- BIWLELKAFXRPDE-PCYOLSTGSA-N di-cis-zeta-carotene Natural products CC(C)=CCCC(C)=CCCC(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(\C)CCC=C(C)CCC=C(C)C BIWLELKAFXRPDE-PCYOLSTGSA-N 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- IWEDIXLBFLAXBO-UHFFFAOYSA-N dicamba Chemical compound COC1=C(Cl)C=CC(Cl)=C1C(O)=O IWEDIXLBFLAXBO-UHFFFAOYSA-N 0.000 description 1
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 1
- 229960001912 dicoumarol Drugs 0.000 description 1
- HIZKPJUTKKJDGA-UHFFFAOYSA-N dicumarol Natural products O=C1OC2=CC=CC=C2C(=O)C1CC1C(=O)C2=CC=CC=C2OC1=O HIZKPJUTKKJDGA-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000000408 embryogenic effect Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000001159 endocytotic effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 1
- 239000003448 gibberellin Substances 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-M hydrosulfide Chemical compound [SH-] RWSOTUBLDIXVET-UHFFFAOYSA-M 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000004731 long QT syndrome Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 208000005340 mucopolysaccharidosis III Diseases 0.000 description 1
- 208000011045 mucopolysaccharidosis type 3 Diseases 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 235000011765 phytoene Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 150000003147 proline derivatives Chemical class 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical class C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 239000012882 rooting medium Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 201000006532 trichorhinophalangeal syndrome type II Diseases 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- HDZZVAMISRMYHH-KCGFPETGSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HDZZVAMISRMYHH-KCGFPETGSA-N 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- BIWLELKAFXRPDE-XXKNMTJFSA-N zeta-Carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)\C)(\C=C\C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)/C BIWLELKAFXRPDE-XXKNMTJFSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
- C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/825—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving pigment biosynthesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/8251—Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576423P | 2011-12-16 | 2011-12-16 | |
| US61/576,423 | 2011-12-16 | ||
| PCT/IL2012/050528 WO2013088446A1 (en) | 2011-12-16 | 2012-12-16 | Compositions and methods for modifying a predetermined target nucleic acid sequence |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014129015A RU2014129015A (ru) | 2016-02-10 |
| RU2663354C2 true RU2663354C2 (ru) | 2018-08-03 |
Family
ID=48611953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014129015A RU2663354C2 (ru) | 2011-12-16 | 2012-12-16 | Композиции и способы для модификации заданной последовательности нуклеиновой кислоты-мишени |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US11458157B2 (enExample) |
| EP (1) | EP2790708B1 (enExample) |
| JP (1) | JP2015500648A (enExample) |
| CN (1) | CN104080462B (enExample) |
| AU (2) | AU2012354062B2 (enExample) |
| BR (1) | BR112014014105B1 (enExample) |
| CA (2) | CA2858801C (enExample) |
| IL (2) | IL253372B (enExample) |
| IN (1) | IN2014MN00974A (enExample) |
| PH (1) | PH12014501360B1 (enExample) |
| RU (1) | RU2663354C2 (enExample) |
| UA (1) | UA115772C2 (enExample) |
| WO (1) | WO2013088446A1 (enExample) |
| ZA (1) | ZA201403785B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2712497C1 (ru) * | 2018-11-26 | 2020-01-29 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Средство разрезания ДНК на основе Cas9 белка из биотехнологически значимой бактерии Clostridium cellulolyticum |
| RU2712492C1 (ru) * | 2018-11-26 | 2020-01-29 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Средство разрезания днк на основе cas9 белка из defluviimonas sp. |
| RU2778156C1 (ru) * | 2021-10-19 | 2022-08-15 | Федеральное государственное бюджетное учреждение науки Институт биологии гена Российской академии наук (ИБГ РАН) | Средство разрезания ДНК на основе Cas9 белка из бактерии Capnocytophaga ochracea |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012028805A2 (pt) | 2010-05-10 | 2019-09-24 | The Regents Of The Univ Of California E Nereus Pharmaceuticals Inc | composições de endorribonuclease e métodos de uso das mesmas. |
| US10920242B2 (en) | 2011-02-25 | 2021-02-16 | Recombinetics, Inc. | Non-meiotic allele introgression |
| US9528124B2 (en) | 2013-08-27 | 2016-12-27 | Recombinetics, Inc. | Efficient non-meiotic allele introgression |
| EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| UA116097C2 (uk) | 2011-12-11 | 2018-02-12 | Зе Стейт Оф Ізраел, Міністрі Оф Агрікалче Енд Руерал Девелопмент, Агрікалчерал Рісьоч Організейшн, (А.Р.О.), Волкані Сентре | Спосіб модуляції провідності устячка рослини |
| GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
| US10058078B2 (en) | 2012-07-31 | 2018-08-28 | Recombinetics, Inc. | Production of FMDV-resistant livestock by allele substitution |
| EP2920319B1 (en) | 2012-11-16 | 2020-02-19 | Poseida Therapeutics, Inc. | Site-specific enzymes and methods of use |
| EP3653212B1 (en) | 2012-12-20 | 2023-04-26 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| KR20170108172A (ko) | 2013-03-14 | 2017-09-26 | 카리부 바이오사이언시스 인코포레이티드 | 핵산-표적화 핵산의 조성물 및 방법 |
| US9902973B2 (en) | 2013-04-11 | 2018-02-27 | Caribou Biosciences, Inc. | Methods of modifying a target nucleic acid with an argonaute |
| GB201311057D0 (en) | 2013-06-21 | 2013-08-07 | Univ Greenwich | Antisense oligonucleotide compositions |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US10538570B2 (en) * | 2013-09-30 | 2020-01-21 | Northwestern University | Targeted and modular exosome loading system |
| US10779518B2 (en) | 2013-10-25 | 2020-09-22 | Livestock Improvement Corporation Limited | Genetic markers and uses therefor |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| DE212015000061U1 (de) | 2014-02-11 | 2017-09-03 | The Regents Of The University Of Colorado, A Body Corporate | CRISPR-ermöglichtes Multiplex Genom Engineering |
| CN106459884A (zh) * | 2014-05-16 | 2017-02-22 | 株式会社钟化 | 土壤杆菌及使用土壤杆菌的转化植物的制造方法 |
| JP2017518082A (ja) * | 2014-06-17 | 2017-07-06 | ポセイダ セラピューティクス, インコーポレイテッド | ゲノム中の特異的遺伝子座にタンパク質を指向させるための方法およびその使用 |
| CA2956224A1 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| ES2968004T3 (es) | 2014-07-30 | 2024-05-06 | Harvard College | Construcción de bibliotecas de sondas |
| CN113699116A (zh) | 2014-12-10 | 2021-11-26 | 明尼苏达大学董事会 | 用于治疗疾病的遗传修饰的细胞、组织和器官 |
| US10738290B2 (en) | 2015-04-21 | 2020-08-11 | Novartis Ag | RNA-guided gene editing system and uses thereof |
| EP3294866A4 (en) * | 2015-05-12 | 2018-12-05 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
| EP3929286A1 (en) | 2015-06-17 | 2021-12-29 | Poseida Therapeutics, Inc. | Compositions and methods for directing proteins to specific loci in the genome |
| IL295616A (en) | 2015-07-31 | 2022-10-01 | Us Health | Adapted cells and treatment methods |
| US20180282763A1 (en) | 2015-10-20 | 2018-10-04 | Pioneer Hi-Bred International, Inc. | Restoring function to a non-functional gene product via guided cas systems and methods of use |
| EP4434589A3 (en) | 2015-10-23 | 2025-05-14 | President and Fellows of Harvard College | Evolved cas9 proteins for gene editing |
| JP7064439B2 (ja) * | 2015-11-04 | 2022-05-10 | アトレカ インコーポレイテッド | 単一細胞に関連する核酸の解析のための、核酸バーコードの組み合わせセット |
| MX2018008344A (es) | 2016-01-11 | 2018-12-06 | Univ Leland Stanford Junior | Proteinas quimericas y metodos para regular la expresion genica. |
| JP7012645B2 (ja) | 2016-01-11 | 2022-01-28 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | キメラタンパク質および免疫治療の方法 |
| US9896696B2 (en) * | 2016-02-15 | 2018-02-20 | Benson Hill Biosystems, Inc. | Compositions and methods for modifying genomes |
| WO2017142999A2 (en) * | 2016-02-18 | 2017-08-24 | President And Fellows Of Harvard College | Methods and systems of molecular recording by crispr-cas system |
| EP3699281A1 (en) | 2016-03-11 | 2020-08-26 | Pioneer Hi-Bred International, Inc. | Novel cas9 systems and methods of use |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| CN105779609A (zh) * | 2016-04-15 | 2016-07-20 | 上海伊丽萨生物科技有限公司 | 一种超敏免疫检测方法 |
| CN109688820B (zh) | 2016-06-24 | 2023-01-10 | 科罗拉多州立大学董事会(法人团体) | 用于生成条形码化组合文库的方法 |
| JP7231935B2 (ja) | 2016-08-03 | 2023-03-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | アデノシン核酸塩基編集因子およびそれらの使用 |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US20190225974A1 (en) | 2016-09-23 | 2019-07-25 | BASF Agricultural Solutions Seed US LLC | Targeted genome optimization in plants |
| CN107880132B (zh) * | 2016-09-30 | 2022-06-17 | 北京大学 | 一种融合蛋白及使用其进行同源重组的方法 |
| AU2017342543B2 (en) | 2016-10-14 | 2024-06-27 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| EP4338799A3 (en) | 2016-10-18 | 2024-06-05 | Regents of the University of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| US20190276881A1 (en) * | 2016-11-08 | 2019-09-12 | President And Fellows Of Harvard College | Multiplexed imaging using merfish, expansion microscopy, and related technologies |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| ES3010559T3 (en) * | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| CN110662556A (zh) | 2017-03-09 | 2020-01-07 | 哈佛大学的校长及成员们 | 癌症疫苗 |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| WO2018176009A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| WO2018183607A1 (en) | 2017-03-30 | 2018-10-04 | Pioneer Hi-Bred International, Inc. | Methods of identifying and characterizing gene editing variations in nucleic acids |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| EP3625340A4 (en) * | 2017-05-18 | 2021-02-24 | Cargill, Incorporated | GENOME EDITING SYSTEM |
| WO2018218150A1 (en) | 2017-05-26 | 2018-11-29 | President And Fellows Of Harvard College | Systems and methods for high-throughput image-based screening |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| EP3645021A4 (en) | 2017-06-30 | 2021-04-21 | Intima Bioscience, Inc. | ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY |
| US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| EP3673054A4 (en) | 2017-08-22 | 2021-06-02 | Napigen, Inc. | ORGANEL GENOME MODIFICATION USING POLYNUCLEOTIDE-GUIDED ENDONUCLEASE |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| CN107759673B (zh) * | 2017-09-27 | 2021-06-04 | 复旦大学 | 可对hbv的dna进行表观甲基化修饰的蛋白分子及其应用 |
| KR20200121782A (ko) | 2017-10-16 | 2020-10-26 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US20200362366A1 (en) | 2018-01-12 | 2020-11-19 | Basf Se | Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a |
| AU2019209428B2 (en) | 2018-01-22 | 2025-06-26 | Endocyte, Inc. | Methods of use for CAR T cells |
| TW202000229A (zh) | 2018-02-23 | 2020-01-01 | 美商安德賽特公司 | Car t細胞療法之順序方法 |
| JP7611702B2 (ja) | 2018-05-06 | 2025-01-10 | エメンドバイオ インコーポレーテッド | ヘテロ接合性elane遺伝子の対立遺伝子の差次的ノックアウト |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| AU2019274597B2 (en) | 2018-05-25 | 2025-11-13 | Pioneer Hi-Bred International, Inc. | Systems and methods for improved breeding by modulating recombination rates |
| US12209259B2 (en) * | 2018-06-27 | 2025-01-28 | Altius Institute For Biomedical Sciences | Nucleases for genome editing |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| CN109355246B (zh) * | 2018-11-21 | 2022-02-11 | 河南农业大学 | 一种拟南芥叶肉细胞原生质体及其制备方法和应用 |
| CN113366116A (zh) | 2018-12-13 | 2021-09-07 | 哈佛学院院长及董事 | 用于merfish和其他应用的扩增方法和系统 |
| WO2020154500A1 (en) | 2019-01-23 | 2020-07-30 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| US20220098621A1 (en) | 2019-02-05 | 2022-03-31 | Emendobio Inc. | Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene |
| MX2021011426A (es) | 2019-03-19 | 2022-03-11 | Broad Inst Inc | Metodos y composiciones para editar secuencias de nucleótidos. |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| EP4100428A4 (en) | 2020-02-04 | 2024-03-06 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | CHIMERIC ANTI-DINITROPHENOL ANTIGEN RECEPTORS |
| US20230312737A1 (en) * | 2020-03-04 | 2023-10-05 | Regents Of The University Of Minnesota | Anti-dr5 polypeptides and methods of use thereof |
| CN111514949B (zh) * | 2020-04-27 | 2020-12-01 | 四川大学 | 一种微流控芯片及其制备方法 |
| WO2021226558A1 (en) | 2020-05-08 | 2021-11-11 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| WO2022170058A1 (en) * | 2021-02-05 | 2022-08-11 | University Of Massachusetts | Prime editor system for in vivo genome editing |
| EP4095243A1 (en) * | 2021-05-25 | 2022-11-30 | European Molecular Biology Laboratory | System for hybridization-based precision genome cleavage and editing, and uses thereof |
| AU2022360286A1 (en) | 2021-10-08 | 2024-05-02 | Pencil Biosciences Limited | Synthetic genome editing system |
| EP4429677A4 (en) * | 2021-11-12 | 2025-08-20 | Targetgene Biotechnologies Ltd | SYSTEMS AND METHODS FOR TRANS-MODULATION OF IMMUNE CELLS BY GENETIC MANIPULATION OF IMMUNOREGULATORY GENES |
| CN114717259B (zh) * | 2022-05-26 | 2023-06-20 | 山西大学 | 一种温控诱导型基因编辑系统及其应用 |
| CN118001292B (zh) * | 2023-09-01 | 2024-11-29 | 香港中文大学(深圳) | 靶向rna的组合物及其用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA42675C2 (uk) * | 1989-12-22 | 2001-11-15 | Апплайд Рєзєч Сістемз, Арс Холдінг Н.В. (Антільські Острови) | Спосіб активації гена, що в нормі транскрипційно мовчить, з геному еукаріотичної клітинної лінії, спосіб модифікації характеристик експресії гена з геному еукаріотичної клітинної лінії, диференційована еукаріотична клітинна лінія (варіанти), днк-конструкт |
| WO2011017315A2 (en) * | 2009-08-03 | 2011-02-10 | Recombinetics, Inc. | Methods and compositions for targeted gene modification |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US4935357A (en) | 1986-02-05 | 1990-06-19 | New England Biolabs, Inc. | Universal restriction endonuclease |
| US6544780B1 (en) | 2000-06-02 | 2003-04-08 | Genphar, Inc. | Adenovirus vector with multiple expression cassettes |
| CA2425917A1 (en) * | 2000-10-13 | 2002-04-18 | Crosslink Genetics Corporation | Artificial transcriptional factors and methods of use |
| EP1501943A4 (en) * | 2002-04-16 | 2005-06-22 | Promega Corp | METHOD FOR IMPROVING APPROVED RECOMBINATION |
| WO2004037977A2 (en) | 2002-09-05 | 2004-05-06 | California Institute Of Thechnology | Use of chimeric nucleases to stimulate gene targeting |
| ES2808687T3 (es) | 2003-08-08 | 2021-03-01 | Sangamo Therapeutics Inc | Métodos y composiciones para escisión dirigida y recombinación |
| DE102004043155A1 (de) | 2004-09-03 | 2006-03-23 | TransMIT Gesellschaft für Technologietransfer mbH | Hochspezifisch mit DNA interagierende Enzym-Konjugate mit programmierbarer Spezifität |
| US20070042404A1 (en) * | 2005-08-19 | 2007-02-22 | Huimin Zhao | Compositions and method for detecting endonuclease activity |
| CA2619833C (en) | 2005-08-26 | 2017-05-09 | Danisco A/S | Use of crispr associated genes (cas) |
| EP2155868A2 (en) * | 2007-04-19 | 2010-02-24 | Codon Devices, Inc | Engineered nucleases and their uses for nucleic acid assembly |
| AU2008335324A1 (en) | 2007-12-07 | 2009-06-18 | Precision Biosciences, Inc. | Rationally-designed meganucleases with recognition sequences found in DNase hypersensitive regions of the human genome |
| US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
| US9404098B2 (en) | 2008-11-06 | 2016-08-02 | University Of Georgia Research Foundation, Inc. | Method for cleaving a target RNA using a Cas6 polypeptide |
| JP2013511979A (ja) * | 2009-11-27 | 2013-04-11 | ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー | キメラエンドヌクレアーゼおよびその使用 |
| EP3456826B1 (en) * | 2009-12-10 | 2023-06-28 | Regents of the University of Minnesota | Tal effector-mediated dna modification |
| JP6208580B2 (ja) | 2010-05-17 | 2017-10-04 | サンガモ セラピューティクス, インコーポレイテッド | 新規のdna結合タンパク質及びその使用 |
| EP2392208B1 (en) | 2010-06-07 | 2016-05-04 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease and their use |
| JP5725864B2 (ja) | 2010-08-06 | 2015-05-27 | 株式会社 資生堂 | エラスターゼ阻害剤 |
| BR112013024337A2 (pt) | 2011-03-23 | 2017-09-26 | Du Pont | locus de traço transgênico complexo em uma planta, planta ou semente, método para produzir em uma planta um locus de traço transgênico complexo e construto de expressão |
| GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
| PL4289948T3 (pl) * | 2012-05-25 | 2025-06-02 | The Regents Of The University Of California | Sposoby i kompozycje do modyfikacji kierowanego na rna docelowego dna i do nakierowanej na rna modulacji transkrypcji |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| US9340800B2 (en) * | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
-
2012
- 2012-12-16 IN IN974MUN2014 patent/IN2014MN00974A/en unknown
- 2012-12-16 JP JP2014546733A patent/JP2015500648A/ja active Pending
- 2012-12-16 BR BR112014014105-3A patent/BR112014014105B1/pt active IP Right Grant
- 2012-12-16 AU AU2012354062A patent/AU2012354062B2/en active Active
- 2012-12-16 CN CN201280062262.XA patent/CN104080462B/zh active Active
- 2012-12-16 WO PCT/IL2012/050528 patent/WO2013088446A1/en not_active Ceased
- 2012-12-16 CA CA2858801A patent/CA2858801C/en active Active
- 2012-12-16 PH PH1/2014/501360A patent/PH12014501360B1/en unknown
- 2012-12-16 EP EP12857977.8A patent/EP2790708B1/en active Active
- 2012-12-16 US US14/364,216 patent/US11458157B2/en active Active
- 2012-12-16 RU RU2014129015A patent/RU2663354C2/ru active
- 2012-12-16 UA UAA201408005A patent/UA115772C2/uk unknown
- 2012-12-16 CA CA3226329A patent/CA3226329A1/en active Pending
-
2014
- 2014-05-23 ZA ZA2014/03785A patent/ZA201403785B/en unknown
-
2017
- 2017-03-03 US US15/449,492 patent/US11278560B2/en active Active
- 2017-03-03 US US15/449,468 patent/US11690866B2/en active Active
- 2017-04-28 US US15/582,384 patent/US10220052B2/en active Active
- 2017-07-09 IL IL253372A patent/IL253372B/en active IP Right Grant
- 2017-07-09 IL IL253373A patent/IL253373A0/en active IP Right Grant
- 2017-11-28 AU AU2017268502A patent/AU2017268502B2/en active Active
-
2023
- 2023-05-15 US US18/317,447 patent/US20240148771A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA42675C2 (uk) * | 1989-12-22 | 2001-11-15 | Апплайд Рєзєч Сістемз, Арс Холдінг Н.В. (Антільські Острови) | Спосіб активації гена, що в нормі транскрипційно мовчить, з геному еукаріотичної клітинної лінії, спосіб модифікації характеристик експресії гена з геному еукаріотичної клітинної лінії, диференційована еукаріотична клітинна лінія (варіанти), днк-конструкт |
| WO2011017315A2 (en) * | 2009-08-03 | 2011-02-10 | Recombinetics, Inc. | Methods and compositions for targeted gene modification |
| WO2011017315A3 (en) * | 2009-08-03 | 2011-06-03 | Recombinetics, Inc. | Methods and compositions for targeted gene modification |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2712497C1 (ru) * | 2018-11-26 | 2020-01-29 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Средство разрезания ДНК на основе Cas9 белка из биотехнологически значимой бактерии Clostridium cellulolyticum |
| RU2712492C1 (ru) * | 2018-11-26 | 2020-01-29 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Средство разрезания днк на основе cas9 белка из defluviimonas sp. |
| WO2020111984A3 (ru) * | 2018-11-26 | 2020-07-23 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Средство разрезания днк |
| WO2020111983A3 (ru) * | 2018-11-26 | 2020-07-23 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Средство разрезания днк |
| RU2778156C1 (ru) * | 2021-10-19 | 2022-08-15 | Федеральное государственное бюджетное учреждение науки Институт биологии гена Российской академии наук (ИБГ РАН) | Средство разрезания ДНК на основе Cas9 белка из бактерии Capnocytophaga ochracea |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2663354C2 (ru) | Композиции и способы для модификации заданной последовательности нуклеиновой кислоты-мишени | |
| JP6559063B2 (ja) | 導入遺伝子のヌクレアーゼ媒介標的化組み込みのための方法および組成物 | |
| RU2723130C2 (ru) | Способы и композиции для встраивания экзогенной последовательности в геном растений | |
| JP5902631B2 (ja) | 標的化ゲノム変更 | |
| JP2016500268A (ja) | トウモロコシにおける特定の遺伝子座に対する精密な遺伝子標的化 | |
| TW202300649A (zh) | Dna修飾酶及活性片段及其變體及使用方法 | |
| CN120322549A (zh) | 利用锁核酸对向导rna化学修饰以用于rna引导的核酸酶介导的基因编辑 | |
| WO2023039346A1 (en) | Temperature regulated crispr-cas systems and methods of use thereof | |
| US20220195446A1 (en) | Plant transformation | |
| HK1203362B (en) | Compositions and methods for modifying a predetermined target nucleic acid sequence | |
| IL232832A (en) | Methods and compositions for altering nucleic acid sequence are known in advance | |
| NZ626105B2 (en) | Compositions and methods for modifying a predetermined target nucleic acid sequence |